SG Americas Securities LLC Reduces Position in iShares Biotechnology ETF $IBB

SG Americas Securities LLC cut its position in iShares Biotechnology ETF (NASDAQ:IBB) by 68.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 13,260 shares of the financial services provider’s stock after selling 28,984 shares during the period. SG Americas Securities LLC’s holdings in iShares Biotechnology ETF were worth $2,239,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Basepoint Wealth LLC purchased a new stake in shares of iShares Biotechnology ETF in the 4th quarter valued at $26,000. Cary Street Partners Financial LLC purchased a new position in shares of iShares Biotechnology ETF during the fourth quarter worth $29,000. Darwin Wealth Management LLC purchased a new position in shares of iShares Biotechnology ETF during the second quarter worth $25,000. Caitlin John LLC acquired a new position in iShares Biotechnology ETF during the fourth quarter valued at $34,000. Finally, Cornerstone Planning Group LLC acquired a new position in iShares Biotechnology ETF during the fourth quarter valued at $35,000. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Down 0.0%

NASDAQ:IBB opened at $190.12 on Thursday. The firm’s fifty day moving average is $172.32 and its two-hundred day moving average is $171.49. iShares Biotechnology ETF has a one year low of $127.11 and a one year high of $191.15.

iShares Biotechnology ETF Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, June 18th. Stockholders of record on Monday, June 15th were paid a $0.0238 dividend. The ex-dividend date was Monday, June 15th. This represents a $0.10 dividend on an annualized basis and a dividend yield of 0.1%.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.